Publication:
The effect of polymorphic metabolism enzymes on serum phenytoin level

Simple item page
dc.contributor.authorGÜNEY, AHMET İLTER
dc.contributor.authorsOzkaynakci, Aydan; Gulcebi, Medine Idrizoglu; Ergec, Deniz; Ulucan, Korkut; Uzan, Mustafa; Ozkara, Cigdem; Guney, Ilter; Onat, Filiz Yilmaz
dc.date.accessioned2022-03-12T20:26:39Z
dc.date.available2022-03-12T20:26:39Z
dc.date.issued2015
dc.description.abstractPhenytoin has a widespread use in epilepsy treatment and is mainly metabolized by hepatic cytochrome P450 enzymes (CYP). We have investigated CYP2C9*2, CYP2C9*3, CYP2C19*2 and CYP2C19*3 allelic variants in a Turkish population of patients on phenytoin therapy. Patients on phenytoin therapy (n = 102) for the prevention of epileptic seizures were included. Polymorphic alleles were analyzed by restriction fragment length polymorphism method. Serum concentrations of phenytoin were measured by fluorescence polarization immune assay method. The most frequent genotype was detected for CYP2C9 wild-type alleles (78.43 %), whereas CYP2C19*2/*2 (5.88 %) was the least frequent genotype group. According to the classification made with both enzyme polymorphisms, CYP2C9*1/*1-CYP2C19*1/*1 (G1: 41.17 %) genotype group was the most frequent whereas CYP2C9*1/*2-CYP2C19*1/*3 (G7: 0.98 %) was the least frequent one. The highest mean phenytoin level (27.95 +/- A 1.85 A mu g/ml) was detected in the G8 genotype group (CYP2C9*1/*3-CYP2C19*2/*3) and the G1 genotype group showed the lowest mean phenytoin level (7.43 +/- A 0.73 A mu g/ml). The mean serum concentration of phenytoin of the polymorphic patients with epilepsy was higher than that for the wild-type alleles both in the monotherapy and polytherapy patients. These results show the importance of the genetic polymorphism analysis of the main metabolizing enzyme groups of phenytoin for the dose adjustment.
dc.identifier.doi10.1007/s10072-014-1961-8
dc.identifier.eissn1590-3478
dc.identifier.issn1590-1874
dc.identifier.pubmed25311916
dc.identifier.urihttps://hdl.handle.net/11424/233509
dc.identifier.wosWOS:000350365000007
dc.language.isoeng
dc.publisherSPRINGER-VERLAG ITALIA SRL
dc.relation.ispartofNEUROLOGICAL SCIENCES
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectEpilepsy
dc.subjectPhenytoin
dc.subjectPharmacogenomics
dc.subjectPharmacokinetics
dc.subjectPharmacotherapy
dc.subjectMetabolism enzyme
dc.subjectJAPANESE EPILEPTIC PATIENTS
dc.subjectGENETIC-POLYMORPHISM
dc.subjectANTIEPILEPTIC DRUGS
dc.subjectCYTOCHROME P4502C9
dc.subjectCYP2C SUBFAMILY
dc.subjectPHARMACOKINETICS
dc.subjectHYDROXYLATION
dc.subjectFREQUENCIES
dc.subjectPOPULATION
dc.subjectVARIANTS
dc.titleThe effect of polymorphic metabolism enzymes on serum phenytoin level
dc.typearticle
dspace.entity.typePublication
local.avesis.ida60871e3-3a76-4d6c-ac7d-89969ac9320c
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.journal.numberofpages5
oaire.citation.endPage401
oaire.citation.issue3
oaire.citation.startPage397
oaire.citation.titleNEUROLOGICAL SCIENCES
oaire.citation.volume36
relation.isAuthorOfPublicationd474fc8a-ae88-487e-b63b-7f506191fb94
relation.isAuthorOfPublication.latestForDiscoveryd474fc8a-ae88-487e-b63b-7f506191fb94

Files

Collections

Research Outputs